Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkInterplay of Immunosuppression and Immunotherapy Among Patients with Cancer and COVID-19

In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form